Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Treasury Shares (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Treasury Shares for 17 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 31.19% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, up 31.19% year-over-year, with the annual reading at $3.5 million for FY2025, 31.19% up from the prior year.
  • Treasury Shares hit $3.5 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $3.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.5 million in Q2 2025 to a low of $1.8 million in Q4 2021.
  • Historically, Treasury Shares has averaged $2.4 million across 5 years, with a median of $2.0 million in 2022.
  • Biggest five-year swings in Treasury Shares: dropped 2.33% in 2023 and later skyrocketed 42.05% in 2024.
  • Year by year, Treasury Shares stood at $1.8 million in 2021, then increased by 8.55% to $1.9 million in 2022, then fell by 0.53% to $1.9 million in 2023, then soared by 39.09% to $2.7 million in 2024, then skyrocketed by 31.19% to $3.5 million in 2025.
  • Business Quant data shows Treasury Shares for VNDA at $3.5 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.